million people affected worldwide
Current Treatments
Psychedelic research currently is in Preclinical
About 30% or one in three of those suffering from depression are dealing with so-called treatment-resistant depression (TRD). The name refers to that these patients have tried at least two treatment options, without success. Psychedelics may offer hope to those suffering from TRD.
This topic is currently a stub, it will be expanded upon in the near future.
Highlighted Institutes
These are the institutes, from companies to universities, who are working on Treatment-Resistant Depression.
Revixia Life Sciences
Revixia Life Sciences is a biotech company developing Salvinorin A (salvia) for substance use disorders (SUD), treatment-resistant depression (TRD), and pain.
Highlighted People
These are some of the best-known people, from researchers to entrepreneurs, working on Treatment-Resistant Depression.
George Goldsmith
George Goldsmith is the CEO, Co-Founder, and Chairman of Compass Pathways, which he has led since July 2016.
Linked Research Papers about Treatment-Resistant Depression
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression
Increased low-frequency brain responses to music after psilocybin therapy for depression
Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use
Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression
Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
The relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature
Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series
Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment
Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression
Effects of psilocybin therapy on personality structure
A Single Dose Of Ayahuasca Modulates Salivary Cortisol In Treatment-Resistant Depression
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression
Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Womens
The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial
Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting
Nitrous Oxide: an emerging novel treatment for treatment-resistant depression
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial
Long-Term Efficacy of Combination Therapy of Transcranial Magnetic Stimulation with Ketamine for Patients with Treatment-Resistant Depression
Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects
Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design